Janux Therapeutics (JANX) – Research Analysts’ Recent Ratings Changes

Janux Therapeutics (NASDAQ: JANX) recently received a number of ratings updates from brokerages and research firms:

• 8/24/2026 – Janux Therapeutics was upgraded by Wolfe Research from “peer perform” to “outperform”. They now have a $23.00 price target on the stock.
• 8/24/2026 – Janux Therapeutics was upgraded by TD Cowen to “strong-buy”.
• 8/7/2026 – Janux Therapeutics was given a new $35.00 price target by Stifel Nicolaus.
• 8/7/2026 – Janux Therapeutics had its price target lowered by Guggenheim from $58.00 to $55.00. They now have a “buy” rating on the stock.
• 7/20/2026 – Janux Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling

In other news, insider Janeen Noel Doyle sold 4,059 shares of the stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $14.03, for a total transaction of $56,947.77. Following the completion of the transaction, the insider directly owned 75,941 shares in the company, valued at $1,065,452.23. This represents a 5.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 7.90% of the stock is owned by company insiders.

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.